COMP <GO>
CYTK vs UNH // FREE CASH FLOW YIELD
Cytokinetics Incorporated (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CYTK 2
— UNH 10
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $62.03 (-1.52%) • MKT CAP: $8.62B
fcf-yield
-6.08%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
fcf-yield
6.25%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYTK VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYTK | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 12.38% | -47.38 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -6.08% | 6.25% | -12.33 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 5.32% | -65.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.53% | -63.53 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 3.33% | +176.67 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 3.09 | -2.64 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.1 | 55.1 | -13.00 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.33 | +0.54 | CYTK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 17.7x | +13.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.62B | $359.43B | -$350.81B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYTK REV | UNH REV | CYTK GROSS % | UNH GROSS % | CYTK FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $88.0M | $447.57B | — | 88.7% | -$534.8M | $16.07B |
| FY 2024 | $18.5M | $400.28B | — | 88.3% | -$399.8M | $20.70B |
| FY 2023 | $7.5M | $371.62B | — | 89.6% | -$414.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYTK // BETA 0.87
UNH // BETA 0.33